申请人:HOFFMANN LA ROCHE
公开号:WO2017042114A1
公开(公告)日:2017-03-16
The present invention relates to compounds of formula (I); hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, S-lower alkyl substituted by halogen or lower alkoxy substituted by halogen, or two neighboring carbon atoms may form on phenyl an additional ring containing -O-CH2-O-; n is 1 to 5; R2 is hydrogen or lower alkyl substituted by halogen; R3 is hydrogen or lower alkyl substituted by halogen; or to pharmaceutically active acid addition salts thereof, to racemic mixtures or to its corresponding enantiomers or optical isomers or stereoisomers thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
本发明涉及式(I)的化合物;hetaryl是一个含有1至3个杂原子(O、S或N)的五元杂芳基团;R1是氢、卤素、低碳链烷基、低碳链烷氧基、被卤素取代的低碳链烷基、被卤素取代的S-低碳链烷基或被卤素取代的低碳链烷氧基,或者邻近的两个碳原子可在苯基上形成一个含有-O-CH2-O-的额外环;n为1至5;R2是氢或被卤素取代的低碳链烷基;R3是氢或被卤素取代的低碳链烷基;或其药用酸加合物、消旋混合物、对映体或光学异构体或立体异构体。这些化合物可用于治疗阿尔茨海默病、脑淀粉样血管病、遗传性脑出血伴淀粉样病变的荷兰型(HCHWA-D)、多梗塞性痴呆、拳击性痴呆或唐氏综合征。